主页 > 医学信息 >
【medical-news】新型镓化合物有望用于治疗耐药性
Novel gallium compound may offer treatment for lymphoma patients with resistant disease
Since the 1970抯, the incidence of non-Hodgkin抯 lymphoma in the U.S. has almost doubled, and despite advances in therapy, the mortality from this disease remains high. More than 58,000 new cases are diagnosed annually and it is estimated that there are now 360,000 Americans living with the disease.
Dr. Chitambar抯 research revealed that the compound, Titan Pharmaceutical抯 gallium maltolate, is an effective anti-tumor agent for inhibiting the growth of human lymphoma cells that are resistant to gallium nitrate. Although the cellular basis for tumor cell resistance to gallium nitrate is not well understood, gallium maltolate appears to be a unique gallium formulation that bypasses the cellular pathways involved in gallium resistance and is able to deliver gallium to molecules within the cell that are involved in inducing cell death.
This pre-clinical, patent-pending therapy is scheduled for clinical trials in the near future. Titan Pharmaceuticals has received an exclusive license from the Medical College of Wisconsin Research Foundation for the use of this intellectual property.
"If proven safe and effective, this agent may offer a viable alternative for a substantial percentage of lymphoma patients whose disease has not responded to gallium nitrate therapy," says Dr. Chitambar.
Dr. Chitambar抯 gallium studies began with basic science research in 1984, leading to his discovery that gallium nitrate inhibits tumor cell growth by blocking an enzyme, ribonucleotide reductase, that is essential for DNA synthesis. He subsequently discovered that when gallium nitrate was combined with hydroxyurea, a chemotherapeutic drug known to inhibit the same enzyme, the anti-cancer activity of gallium nitrate was synergistically boosted.
This preclinical discovery led to a clinical trial at Froedtert Hospital in which gallium nitrate and hydroxyurea were combined to treat patients with advanced relapsed non-Hodgkin抯 lymphoma, and proved to be effective in approximately 40 percent of patients with this disease.
Dr. Chitambar抯 research, at the MACC (Midwest Athletes Against Childhood Cancer) Fund Research Center, focuses on the role of metals, especially the role of iron, in DNA synthesis and the growth of malignant cells. A major emphasis of his work is to develop strategies to modulate iron-dependent malignant cell growth and to enhance the efficacy of cancer chemotherapy by interrupting the flow of iron and other metals within cells. His research also focuses on unraveling cellular processes involved in tumor cell death and tumor cell resistance to metal-based drugs.
Gallium complexes are among the therapeutic strategies being investigated to inhibit tumor growth. Dr. Chitambar抯 research is also leading to a better understanding of iron metabolism in malignant cells and to the development of novel cancer treatment strategies directed at targeting metal-dependent tumor cell growth. 本人已经认领此文. 如在48小时内未能提交译文, 其他战友可自由认领. Novel gallium compound may offer treatment for lymphoma patients with resistant disease
Since the 1970抯, the incidence of non-Hodgkin抯 lymphoma in the U.S. has almost doubled, and despite advances in therapy, the mortality from this disease remains high. More than 58,000 new cases are diagnosed annually and it is estimated that there are now 360,000 Americans living with the disease.
从上世纪70年代开始，美国非何杰金氏淋巴瘤的发病率几乎翻了一倍。尽管在治疗上获得进展，但是该病的死亡率仍然很高。每年有超过58，000新发病人，据估计目前美国有360，000人带病生存。
Dr. Chitambar抯 research revealed that the compound, Titan Pharmaceutical抯 gallium maltolate, is an effective anti-tumor agent for inhibiting the growth of human lymphoma cells that are resistant to gallium nitrate. Although the cellular basis for tumor cell resistance to gallium nitrate is not well understood, gallium maltolate appears to be a unique gallium formulation that bypasses the cellular pathways involved in gallium resistance and is able to deliver gallium to molecules within the cell that are involved in inducing cell death.
Chitambar博士的研究表明，Titan 药物公司镓麦芽酚化合物是有效抑制耐硝酸镓人淋巴瘤细胞生长的抗肿瘤制剂，虽然肿瘤细胞耐硝酸镓的细胞机制还不是非常清楚，但是镓麦芽酚显示独特的镓结构，可绕过镓耐药的细胞途径，可将镓传递到引起细胞死亡的细胞内分子。
This pre-clinical, patent-pending therapy is scheduled for clinical trials in the near future. Titan Pharmaceuticals has received an exclusive license from the Medical College of Wisconsin Research Foundation for the use of this intellectual property.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-04-07 18:13
医学,生命科学网